BPC-157: read the human-pilot evidence first, then the animal-recovery literature beneath it.

What BPC-157 is, on one screen

BPC-157 is a synthetic 15-amino-acid peptide — sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular weight 1419.53 Da, CAS 137525-51-0 — derived from a partial sequence of a protein found in human gastric juice. Its authors call it a "stable gastric pentadecapeptide" because it is reported stable in gastric juice. It is not a naturally circulating hormone, and it is not an FDA-approved drug.

The honest BPC-157 record reads in two tiers. The top tier is thin: as of 2025 reviews, only three small human pilot studies exist ^[6]. The lower tier is deep: dozens of rodent and in-vitro studies describe accelerated tissue repair and a consistent angiogenic mechanism. This site keeps those tiers visibly separate, because a rat result is not human evidence — and most of what gets repeated online collapses the two.

What the animal work most consistently shows is repair through new blood-vessel growth. In a fully transected rat Achilles tendon, BPC-157 improved biomechanical and functional recovery and restored tendon integrity versus untreated controls ^[1]. In gastric-ulcer models it reduced ulcer area, with an inhibition ratio of 45.7-65.6% at the higher doses tested ^[4]. The proposed engine is the mechanism of action: up-regulation and internalization of the VEGFR2 receptor with downstream Akt-eNOS (nitric-oxide) signaling ^[3].

BPC-157 Peptide: Identity and Sequence

The BPC-157 peptide is a pentadecapeptide — fifteen amino acids, no more — assembled as GEPPPGKPADDAGLV (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with molecular formula C62H98N16O22 and PubChem CID 108101 ^[2]. It is frequently supplied as the acetate salt. In the historical industrial development program it carried the designations PL-10, PLD-116, and PL 14736, under which it entered early inflammatory-bowel-disease trials ^[6].

Unlike a growth hormone or a peptide hormone, BPC-157 has no endogenous circulating pool; it is a synthetic stable fragment of a larger gastric-juice protein. That distinction matters for reading the literature: the peptide is studied as a cytoprotective agent — protecting and helping rebuild tissue — rather than as a replacement for any hormone the body already makes.

What does BPC-157 do in the body?

In animal models BPC-157 is described as a cytoprotective peptide that promotes tissue repair largely through angiogenesis — the growth of new blood vessels. The best-characterized pathway is VEGFR2 up-regulation and internalization, feeding into Akt and endothelial nitric-oxide synthase (eNOS) signaling ^[3]. In ischemic rat muscle this is associated with faster blood-flow recovery, and the effect is blocked when receptor internalization is inhibited ^[3]. Reported secondary routes include the FAK-paxillin pathway and growth-hormone-receptor sensitization in tendon fibroblasts.

Where the evidence is thin, and where it is not

The reproducibility across rodent recovery models is itself a finding — tendon, gut, vasculature, the same direction of effect across many studies ^[1][3][4]. The limits are equally clear. Much of the foundational work comes from a single research group, which newer authors explicitly flag as a replication question ^[6]. There is no large, controlled human efficacy trial of BPC-157 in any indication. The first-in-human intravenous safety pilot enrolled two adults ^[5].

For the structured version of all of this — the BPC-157 recovery research page with its three human pilot studies and tendon healing studies, the research dosing context, and the BPC-157 legal status — use the console pages. The frequently asked questions page answers the twenty-five questions people most often ask, and every quantitative claim resolves to the references and citations.